A Two-Arm Study of Preoperative Nilotinib for Patients With Resectable or Potentially Resectable Gastrointestinal Stromal Tumour (GIST).
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2012
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 10 Aug 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Jan 2011 New trial record